Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Kevin Grogan is appointed as CEO of Flexible Packaging, DS Smith, Plastics Division

DS Smith Plastics -a division of DS Smith Plc- is pleased to announce the appointment of Kevin Grogan to CEO of the Flexible Packaging business organization.

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

DS Smith Plastics -a division of DS Smith Plc- is pleased to announce the appointment of Kevin Grogan to CEO of the Flexible Packaging business organization. In this capacity, he will be responsible for all of Plastics' Flexible Packaging operations worldwide.

Mr. Grogan joined DS Smith, Plastics Division in 2011 as President of the Flexible Packaging business in North America. He has over 20 years' experience within the packaging industry including executive roles at Pactiv Corporation, Tegrant and SCA Packaging. Mr. Grogan holds a Master of Business Administration (MBA) from the University Of Chicago Booth School Of Business, as well as a Bachelor's degree in Finance from the University of Notre Dame.

The Flexible Packaging business of DS Smith Plastics operates from eleven different manufacturing and sales sites in seven countries which include Australia, Bulgaria, Germany, New Zealand, Slovakia, Thailand and the United States of America.

Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?